ArticleCancer immunology research2019
Human CD4
Abstract read
In one paragraph
Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.Journal for immunotherapy of cancer · 2024Article
- Review
- Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma.medRxiv : the preprint server for health sciences · 2024Article
- Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.Cell reports. Medicine · 2024Article
- T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma.The Journal of clinical investigation · 2024Article
- The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.Journal for immunotherapy of cancer · 2023Article
- The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.bioRxiv : the preprint server for biology · 2023Article
- LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition.Frontiers in immunology · 2023Article
- T-Cell Mediated Immunity in Merkel Cell Carcinoma.Cancers · 2022Review
- Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.Journal for immunotherapy of cancer · 2022Article
- Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.Journal for immunotherapy of cancer · 2022Article
- Merkel Cell Polyoma Virus and Cutaneous Human Papillomavirus Types in Skin Cancers: Optimal Detection Assays, Pathogenic Mechanisms, and Therapeutic Vaccination.Pathogens (Basel, Switzerland) · 2022Review
- T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.International journal of molecular sciences · 2021Review
- Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.The Journal of investigative dermatology · 2021Review
- Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.International journal of molecular sciences · 2021Review
- Merkel Cell Carcinoma: New Trends.Cancers · 2021Review
- From Merkel Cell Polyomavirus Infection to Merkel Cell Carcinoma Oncogenesis.Frontiers in microbiology · 2021Review
- Non-Melanoma Skin Cancers: Biological and Clinical Features.International journal of molecular sciences · 2020Review
- Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.Molecular carcinogenesis · 2020Review
- Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8Cancer immunology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Natalie V LonginoDepartment of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.
Junbao YangTranslational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.
Jayasri G IyerDepartment of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.
Dafina IbraniDepartment of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.
I-Ting ChowTranslational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.
Kerry J LaingDepartment of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington.ORCID 0000-0001-9245-5325
Victoria L CampbellDepartment of Medicine, Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington.
Kelly G PaulsonDepartment of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.
Rima M KulikauskasDepartment of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.
Candice D ChurchDepartment of Medicine, Division of Dermatology, University of Washington, Seattle, Washington.
Eddie A JamesTranslational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.ORCID 0000-0002-7217-5729
Paul Nghiem *Department of Medicine, Division of Dermatology, University of Washington, Seattle, Washington. pnghiem@uw.edu.ORCID 0000-0003-2784-963X
William W Kwok *Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.
David M Koelle *Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, Washington.ORCID 0000-0003-1255-9023
University of Washington · USVirginia Mason Medical Center · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MUnderstand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI Justin J Taylor · 2019 to 2026
$22.7MEnvironmetal Pathology/Toxicology Training ProgramT32ES007032 · NIEHS · UNIVERSITY OF WASHINGTON · PI FAUSTMAN, ELAINE M, ROSENFELD, MICHAEL E · 1985 to 2023
$10.7MPathogenetic and prognostic studies for improved therapy of Merkel cell carcinomaK24CA139052 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2009 to 2018
$1.8MNCI NIH HHS K24 CA139052NCI NIH HHS P01 CA225517NCI NIH HHS P30 CA015704NIEHS NIH HHS T32 ES007032
Abstract
Although CD4
Indexed as
CarcinogenesisCarcinoma, Merkel CellCD4-Positive T-LymphocytesCell Line, TumorEpitopesHealthy VolunteersHumansMerkel cell polyomavirusOligopeptidesRetinoblastoma ProteinSkin NeoplasmsEpitopesOligopeptidesRetinoblastoma Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.